PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications.

Abstract

The new immunotherapy targeting the programmed cell death 1 (PD-1) receptor and its cognate ligand PD-L1 has renewed hopes of eradicating the most difficult human cancers to treat. Among these, there are the poorly differentiated and anaplastic thyroid cancers, unresponsive to all the therapies currently in use. In the present review we will summarize information regarding the expression of PD-L1 in the different thyroid cancer histotypes, its correlation with clinicopathological features, and its potential prognostic value. Then, we will evaluate the available data indicating the PD-1/PD-L1 axis as a promising target for thyroid cancer therapy.

• Authors: Salvatore Ulisse, Chiara Tuccilli, Salvatore Sorrenti, Alessandro Antonelli, Poupak Fallahi, Eleonora D'Armiento, Antonio Catania, Francesco Tartaglia, Maria Ida Amabile, Laura Giacomelli, Alessio Metere, Nicola Cornacchini, Daniele Pironi, Giovanni Carbotta, Massimo Vergine, Massimo Monti, Enke Baldini
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 20 Issue 6 (Mar 20 2019) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 30897754 (Publication Type: Journal Article, Review)

Chemical References

• Biomarkers, Tumor
• Programmed Cell Death 1 Receptor

Topics

• Animals
• Biomarkers, Tumor (metabolism)
• Humans
• Prognosis
• Programmed Cell Death 1 Receptor (metabolism)
• Thyroid Neoplasms (metabolism, pathology)